An investigation of Cutimed Sorbact as an antimicrobial alternative in wound management

Similar documents
Non-medicated wound dressing as an antimicrobial alternative in wound management

THERAPIES. HAND IN HAND. Need safe and efficient infection prevention and management? 1 The Cutimed. Closing wounds. Together.

Surgical site infections have been

easy made Cutimed Sorbact

DRESSING SELECTION. Rebecca Aburn MN NP Candidate

Agenda (45 minutes) Some questions for you. Which wound dressing? Dressing categories/types. Summary

An evaluation of the efficacy of Cutimed Sorbact in different types of non-healing wounds Sylvie Hampton

DRESSING SELECTION SIMPLIFIED

Your guide to wound debridement and assessment. Michelle Greenwood. Lorraine Grothier. Lead Nurse, Tissue Viability, Walsall Healthcare NHS Trust

Essity Internal. Taking the fear out of wound infection: conquering everyday issues

Tissue Viability Service Wound Management Primary Care Formulary 2017

HydroTherapy: A simple approach to Wound Management

Choosing an appropriate dressing for chronic wounds Denise Bell BSc, RGN and Dot Hyam RGN, DipHE

MEDIZIN& PRAXIS. Vacutex an effektive debridement procedure for the treatment of decubitus. Decubitus. Special. A. Probst

The primary function of low-adherence wound contact

Foam dressings have frequently

Appropriate Dressing Selection For Treating Wounds

Tissue Viability Service Wound Management Primary Care Formulary 2017

Silver Dressings. Sajida Khatri PrescQIPP Primary Care Lead.

A Pilot Study of Oxygen Therapy for Acute Leg Ulcers

Cost and dressing evaluation of hydrofiber and alginate dressings in the management of community-based patients with chronic leg ulceration

4-layer compression bandaging system (includes microbe binding wound contact layer) Latex-free, 4-layer compression bandaging system

Mean percent reduction in ulcer area from baseline at six weeks 62 % SANTYL Ointment + supportive care* + sharp debridement 1 (P<0.

Venous Leg Ulcer. A Complete Solution. Therapy Approach with Adapted Products

Do all foam dressings have the same efficacy in the treatment of chronic wounds? Janice Bianchi, David Gray, John Timmons, Sylvie Meaume

Clinical observation study in 624 patients confirms good efficacy and tolerability

SDMA Categorisation of Wound Care and Associated Products

Disclosures for Tarik Alam. Wound Bed Preparation. Wound Prognosis. Session Objectives. Debridement 4/26/2015

Wound Healing Community Outreach Service

The Triangle of Wound Assessment

Exudate in the early stages of wound healing

Clinical observation study in 624 patients confirms good efficacy and tolerability

Use of a DACC-coated antimicrobial dressing in people with diabetes and a history of foot ulceration

Lower Extremity Wound Evaluation and Treatment

Prontosan. Clean. Easy Wound Healing. Wound Cleansing

Multi-Center Clinical Results with PluroGel PSSD in Chronic Wounds

Wound Healing: General Principles. Mansour Dib MD

PRODIGY Quick Reference Guide

Venous Leg Ulcers. Care for Patients in All Settings

The impact of introducing a new foam dressing in community practice

ULCERS 1/12/ million diabetics in the US (2012) Reamputation Rate 26.7% at 1 year 48.3% at 3 years 60.7% at 5 years

The clinical performance of PermaFoam cavity in the management of chronic wounds: a prospective, non-randomized clinical observation study

Wound management accounts for

Wound management accounts for

Title: A Systematic review of Dialkylcarbomoylchloride (DACC) impregnated dressings in

GP Practice Woundcare Formulary

Dressings do not heal wounds properly selected dressings enhance the body s ability to heal the wound. Progression Towards Healing

Venous Leg Ulcer. A Complete Solution. Therapy Approach with Adapted Products

Categorisation of Wound Care and Associated Products

CASE 1: TYPE-II DIABETIC FOOT ULCER

Advancing the science of wound bed preparation

Management of Complex Wounds with Vacuum Assisted Closure

Advazorb. Hydrophilic foam dressing range

DACC antimicrobial technology:

Evaluating the use of a topical haemoglobin spray as adjunctive therapy in non-healing chronic wounds a pilot study Liezl Naude

Resources to Guide the Management of Suspected Infection in Chronic Wounds

This article is based on a symposium held

How Wounds Heal: A Guide for the Wound-care Novice

Graduated compression and moist wound

Supporting healthcare professionals in taking control of the infection risk with ACTICOAT Flex TAKE CONTROL. of the infection risk in chronic wound

INTRODUCTION TO WOUND DRESSINGS

Acute and Chronic WOUND ASSESSMENT. Wound Assessment OBJECTIVES ITEMS TO CONSIDER

Wound debridement: guidelines and practice to remove barriers to healing

addressed to optimise wound healing.

Impregnated tulle dressing containing silver promotes healing of wounds and treats the wound margins Atrauman Ag tested in clinical practice

Understanding our report and advice: Antimicrobial wound dressings (AWDs) for chronic wounds

South West Regional Wound Care Toolkit F. PRINCIPLES OF TREATMENT BASED ON ETIOLOGY (TREAT THE CAUSE)

2008 American Medical Association and National Committee for Quality Assurance. All Rights Reserved. CPT Copyright 2007 American Medical Association

Advanced Wound Care. Cut Shape Innovate

Wound Assessment Report

Abilar Questions and Answers

Many patients with chronic wounds. Case reports. The use of Prontosan in combination with Askina Calgitrol : an independent case series

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research

Making the Most of your Dressing Products Catherine Hammond CNS/CNE

NPUAP Mission. Clinical Practice Guidelines: Wound Dressings for the Management of Pressure Injuries. npuap.org

An observational evaluation of a new foam adhesive dressing

DEBRIDEMENT. Professor Donald G. MacLellan Executive Director Health Education & Management Innovations

Product overview

Uncovering the Pressure Ulcer Coverup Rhonda Kistler RN MS CWON Wound Care Concepts Gentell

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Hemostasis Inflammatory Phase Proliferative/rebuilding Phase Maturation Phase

1/5. Introduction. Primary endpoint Time to reach readiness for closure by surgical intervention or left for closure by secondary intention

Disclosures. Outpatient NPWT Options Free up Hospital Beds, but Do They Work? Objectives. Clinically Effective: Does it Work?

d e c u t a s t ar Modern wound care in all wound phases

Appropriate use of silver dressings

Consider the possibility of pressure ulcer development

Diagnosing wound infection - a clinical challenge

Fundamentals Of Wound Management. Julie Hewish Senior Tissue Viability Nurse

Evaluation of the Use of a Silver Collagen Amorphous Gel in the Healing of Post Surgical and Dehisced Lesions

TIME CONCEPT AND LOCAL WOUND MANAGEMENT

Catch or Kill? How DACC technology redefines antimicrobial management. An educational supplement in association with

The compatibility of INTRASITE Gel and ACTICOAT : An In-Vivo and In-Vitro assessment. *smith&nephew

Anseong Factory : 70-17, Wonam-ro, Wongok-myeon, Anseong-si, Gyeonggi-do , REPUBLIC OF KOREA

UNIQUE SURGICAL DRESSING. StopBac. bac GRADE MEDICAL.

Sores That Will Not Heal

Palliative Care. EPUAP/NPUAP Publish New Pressure Ulcer Guidelines for. Treatment. Improving Quality of Care Based on CMS Guidelines 39

Beyond the Basics ImprovingYour Wound Care Knowledge. Berna Goldentyer RN, BSN, CWOCN Kathy Hugen RN, BSN, CWOCN

The Power of a Hydroconductive Wound Dressing with LevaFiber Technology

Galen ( A.D) Advanced Wound Dressing

Transcription:

An investigation of Cutimed Sorbact as an antimicrobial alternative in wound management G Kammerlander, E Locher, A Suess-Burghart, B von Hallern, P Wipplinger Abstract Background: Antimicrobial dressings play a major role in the effective management of both acute and chronic wounds. The study featured in this article investigates whether the use of a new dressing, which incorporates the principle of hydrophobic interaction, offers an effective form of antimicrobial management in chronic wounds. Aims: This study aimed to assess the efficacy of Cutimed Sorbact (BSN medical Ltd, Hull) in the management of chronic wounds. Methods: A 116-patient multi-centre European study was used. Results: The study results demonstrate that 81% of patients with an infected wound received effective treatment using the new dressing. Twenty-one per cent of patients wounds healed during the study and a further 7 showed an improvement in wound healing. Reductions in wound pain were reported and both patients and healthcare professionals reported the dressing as being easy to use. A range of secondary dressings were used during the study and no compatibility issues were reported. The principle of hydrophobicity in dressings offers an alternative to the use of established antimicrobial products. Conclusions: The adaptability of a bacterial binding product offers a great deal to healthcare professionals involved in the management of wounds and should be considered a welcome development Conflict of interest: This study was performed in response to the application and request of the Academy for Certified Management and was subsequently sponsored by BSN medical GmbH (Hamburg) KEY WORDS care Chronic wounds Antimicrobial dressings bed preparation Bacterial binding Hydrophobic interaction The control of bacterial load as an approach to the management of chronic wounds has been known for many years (Cutting and Harding, 1994). The theory of G Kammerlander is Director of the Academy for Certified Management in Embrach/Zurich (Switzerland) and of the Competence Centre in Linz (Austria), E Locher is Certified Manager, Management at Outpatient Clinic, Kallern, Hinterbuhl, Switzerland, A Suess-Burghart is Certified Manager, Health Assistant and Nurse at Stadtisches Klinikum GmbH, and Foot Centre, Diabetology Day Clinic, Munich, Germany, B von Hallern is Head Nurse of the Emergency Admission Centre, Elbe Hospital Stade, Germany, P Wipplinger is Head of the Competence Centre, Linz, Austria 10 s UK, 2008, Vol 4, No 2 wound bed preparation (Sibbald et al, 2000; Schulz et al, 2003) formalised the concept based on three crucial areas of management important in the management of chronic wounds: debridement, bacterial balance and moisture balance. The antimicrobial products currently available encompass a range of techniques that use elemental approaches; these products use active ingredients like silver (e.g. silver sulfadiazine, nanocrystalline silver, silver nitrate, colloidal silver) to control bacterial load. The bacterial binding wound dressing Cutimed Sorbact (BSN medical Ltd, Hull) offers an alternative approach to wound healing or the management of bioburden. This mode of action is based on hydrophobic (water repellent) interaction (Figure 1). Hydrophobic particles naturally aggregate in an aqueous environment, held together by surrounding water molecules. Cutimed Sorbact dressings are coated with a fatty acid derivative (dialkylcarbamoyl chloride, DACC) providing the product with strongly hydrophobic properties. As wound bacteria also have hydrophobic characteristics, they become physically bound to the dressing fibres and are subsequently removed from the wound when the dressing is changed (Figures 2 and 3). This bacteria binding effect is already well established (Ljungh et Water molecule Hydrophobic particle Figure 1. Hydrophobic interaction. Hydrophobic interaction

Cutimed Sorbact dressing microbes Hydrophobic interaction Removal of Cutimed Sorbact and microbes Figure 2. Hydrophobic action of Cutimed Sorbact. al, 2006) and is of particular interest in wound care as it requires no local antiseptic or antibiotic agent to treat wounds displaying local signs of infection or critical colonisation. This is important as the wound is not charged with chemically active agents and therefore there are no risks of cytotoxic reactions or development of bacterial resistances. Aims This study was performed to obtain detailed information about the efficacy of Cutimed Sorbact in the management of secondary healing wounds. Method The study was undertaken between 2003 and 2006 in four hospitals with specialist wound healing centres in Munich and Stade, in Germany; Linz in Austria; and Kallern in Switzerland. These centres were chosen because they all have certified wound managers from the Academy of Certified Management and all have the same background and knowledge regarding the treatment of chronic and acute wounds. All the healthcare professionals 12 s UK, 2008, Vol 4, No 2 Figure 3. Electron microscope image of Cutimed Sorbact with bacteria attached. using the product were accredited wound specialists and were briefed on the use and therapeutic indications of the dressing at the start of the study. They were instructed to use Cutimed Sorbact as part of the therapeutic regimen they would normally use for the patients involved in the study. Patients presenting with a wound that was deemed to be at high risk of infection were asked if they wanted to take part in the study. Enrolment in the study was slow initially, but increased in pace once initial scepticism regarding the product was overcome by positive results. During the treatment, practitioners became confident that the product performed well, and more patients were recruited to the study. In order to test the efficacy of Cutimed Sorbact, the study questioned whether it could: 8 Reduce signs of perifocal inflammation 8 Reduce or eliminate local infection 8 Improve the course of wound healing 8 Demonstrate subjective tolerability by patients 8 Demonstrate broad compatibility with other wound management products 8 Provide easy product handling during dressing changes. A wide variety of wounds healing by secondary intention (aetiologies shown in Figure 4) were treated using the structured approach to wound management normally adopted by the participating clinics. A recognised protocol was followed based on the Healing Continuum (Gray et al, 2006), with appropriate management provided dependent on the stage of wound healing. healing progression was monitored as per normal practice; a standardised case report form was used to monitor and record the progress. To assess wound healing, wounds were assigned to one of the following four groups: 8 Stagnating if the final wound assessment exhibited neither deterioration nor a marked improvement in the wound compared with the initial assessment 8 Worse if the clinical signs of inflammation had increased, sloughy layers or necrotic material had formed for the first time or the proportion of granulation or epithelial tissue was reduced 8 Improved if the clinical signs of inflammation were reduced, the wound became clean or an increased amount of granulation or epithelial tissue was observed. Successful cleaning of the wound bed followed by surgical wound closure was also classified as improved 8 Cured if the original skin defect showed complete, closed and epithelialised scar formation. A wound was considered infected if the typical local infection signs, and possibly signs of a spreading infection, were observed. The evaluation presented in this paper used the following signs of clinical infection: 8 Skin irritation 8 Redness 8 Infiltration 8 Swelling 8 Pain 8 Exudate 8 Odour. In the worst cases wound swabs were taken for analysis. The condition of the peri-wound skin was also observed. Patients enrolled

18% 2 10% 8% 7% 9% Figure 4. Aetiologies of the wounds included in the study. 1% 8% 28% 18% 1% 1% 1 Figure 5. Positions of wounds included in the study. Rate of wound infections at the beginning of treatment with Cutimed Sorbact (n=116) 84% 81% Pressure ulcer Venous leg ulcer Arterial leg ulcer Mixed leg ulcer Diabetic foot ulcer Ulcer of other aetiology Postinfectious Posttraumatic Postoperative Burn, corrosion Toe (1) Foot Sole of foot Ankle, heel Calf Thigh Sacral region Trochanter Genital region Head Torso Hand, arm Gluteal region Results after treating infected wounds with Cutimed Sorbact (n=98) 19% No wound infection: 18 patients () Still infection signs: 19 patients (19%) infection: 98 patients (84%) Elimination of infection: 79 patients (81%) Figure 6. Number of wound infections at the start and end of treatment. in the study with a systemic infection (an infection in addition to the local wound infection) were treated with antibiotics according to normal practice. This group accounted for less than 10% of the study. Tolerability by patients was determined using pain assessment. This was documented at every dressing change (n=1150) using a visual analogue pain scale extending from 0 10 (0 being no pain; 10 being severe pain). This parameter could not be established in one of the patients due to unconsciousness. Another pain-related question put to the patients (n=115) concerned any subjective sensations felt directly after the application of Cutimed Sorbact at each dressing change. The feel of the dressing was rated as neutral, unpleasant, pleasant, or very pleasant. The secondary dressing used to maintain the optimum wound environment was also noted. managers were left to choose the secondary dressing (e.g hydrogels, alginates, hydrocolloids) that would be most suitable for the wound (e.g. based on the level of exudate). At every dressing change practitioners were asked to comment on the handling and application of the product. They could rate it as very good, good, satisfactory or unsatisfactory. Additional comments were also encouraged. Results A total of 116 patients were enrolled in the study. The profile of these patients was as follows: 8 Mean treatment period: 37 days (range = 4 134 days) 8 Mean age: 63 years (range = 27 95 years) 8 Mean age of the wound at start of treatment: six months (range = 1 day 54 months) 8 Gender distribution: 54 women, 62 men 8 Recorded dressing changes: 1,150 8 Mean frequency of dressing change: 2.5 per week 8 aetiologies and locations are shown in Figures 4 and 5. 14 s UK, 2008, Vol 4, No 2

1% 6% 6% 27% 21% 7 Stagnating Worse Improved Cured 6 Very pleasant Pleasant Unpleasant Neutral Figure 10. Patients subjective assessment of the application of Cutimed Sorbact. Figure 8. Final outcomes of the wound healing process. At start of treatment 4. 33.0% 10.4% 52. 0 = No pain (52.) 0 = No pain (83.) 1 3 = Mild pain (33.0%) 1 3 = Mild pain (14.8%) 4 6 = Moderate pain (4.) 4 6 = Moderate pain (0.9%) 7 10 = Severe pain (10.4%) 7 10 = Severe pain (0.9%) Figure 9. A comparison of pain levels at the beginning and end of treatment. 8 Concomitant diseases included, diabetes (39%), peripheral arterial occlusive disease (PAOD) (39%), chronic venous insufficiency (CVI) (9%), hemiplegia (7%), paraplegia (), renal insufficiency () and cardiac failure (). Results for infected wounds The author divided wounds into infected and non-infected rather than into critically colonised and infected. Based on normal clinical criteria for the centres, a wound was considered infected if local signs were observed at the initial assessment. In 98 (84%) of the 116 documented wounds, a wound infection was diagnosed at the start of treatment. One patient developed At end of treatment 14.8% 83. 0.9% 0.9% a wound infection, not present at enrolment to the study, during the course of treatment. There were no incidents of a recurrence of a successfully treated wound infection. Less than 10% of the patients suffering from wound infection received additional antibiotic treatment (Figure 6). Of the infections present at the start of treatment (n=98), the following outcomes were observed: 8 In 79 patients (81%), the wound infection was successfully treated 8 In 19 cases (19%), the wound infection was not completely cured at the end of the documented treatment period. Results for the wound healing process To evaluate the clinical efficacy of Cutimed Sorbact as an antimicrobial wound dressing, the documented treatment courses and final outcomes were assigned to one of four groups with the following results (Figure 8): 8 Stagnating seven cases, 6% 8 Worse one case, 1% 8 Improved 84 cases, 7 8 Cured 24 cases, 21%. Results for wound pain Pain can occur as a symptom of a wound infection but can also result from inadequate local treatment. A comparison of the pain data generated in 115 patients at the beginning and end of treatment revealed a marked improvement in pain symptoms during the course of therapy (Figure 9): 8 0 (no pain): 52. (beginning); 83. (end) 8 1 3 (mild pain): 3 (beginning); 14.8% (end) 8 4 6 (moderate pain): 4. (beginning); 0.9% (end) 8 7 10 (severe pain): 10.4% (beginning); 0.9% (end). Results for patients subjective perception after application of the wound dressing Some antiseptics such as silver dressings or highly absorbent wound dressings can cause unpleasant sensations or pain. However, patients identified the dressing as pleasant or very pleasant with no pain, burning, skin irritation or negative sensations) in 71% of cases and in only of cases was the dressing identified as unpleasant (Figure 10). There were no instances reported by patients of any undesirable side-effects of the various dressing combinations. 16 s UK, 2008, Vol 4, No 2

0% 28% 69% Very good Good Satisfactory Unsatisfactory Figure 11. Product handling as assessed by clinicians. Furthermore, Cutimed Sorbact did not cause discolouration in any of the wounds and no product-specific odour was reported during the course of treatment. Results for product handling Depending on the type of wound treated, the healthcare professionals had various product variations at their disposal (e.g. absorbent pads, swabs, round swabs, ribbon gauzes all part of the Cutimed Sorbact range). Suitable variations were chosen according to patients individual wound (location, depth, topography, area). In 97% of cases the dressing change was rated as good or very good. This demonstrates that healthcare professionals were extremely satisfied with the handling characteristics of the dressings (Figure 11). Results for compatibility During the study, and according to the stage of wound healing, Cutimed Sorbact was combined with other dressings where necessary. Depending on the degree of exudate present, amorphous hydrogels, alginates, hydrocolloids, foam dressings, TenderWet (Hartmann, Heywood), film dressings or absorbent swabs were all used together with Cutimed Sorbact. Participating clinicians rated hydrogels as the best combination. Ointment dressings were not used as fatty substances can inhibit the bacterial binding effect of Cutimed Sorbact. Discussion In this study, Cutimed Sorbact was tested under the day-to-day conditions normally found in the participating clinics. The outcomes measured covered the many parameters used by healthcare 18 s UK, 2008, Vol 4, No 2 professionals to choose products, as well as those related to clinical efficacy. Despite initial scepticism, Cutimed Sorbact achieved a good level of efficacy as an antimicrobial product within a phased programme of wound care. Using Cutimed Sorbact in this study, 81% of wounds showing signs of infection at the start of treatment were healed and in 9 of cases there was an improvement in wound healing or a complete cure. This study aimed to test whether Cutimed Sorbact could reduce signs of perifocal inflammation, reduce or eliminate local infection, demonstrate subjective tolerability by patients, demonstrate broad compatibility with other wound management products and provide easy product handling during dressing changes. These were all achieved or exceeded during the study. In particular, the consistently easy handling convinced healthcare professionals of the versatility and value of this alternative to current antimicrobial dressings. Recommendations The study found that it is important to choose a secondary dressing or fixative that keeps the wound moist to avoid possible sticking to the wound by the dressing. Conclusion Antimicrobial dressings play a major role in the effective management of both acute and chronic wounds. This study demonstrated that Cutimed Sorbact is a cost-effective alternative to commonlyused antimicrobial products and as the dressings are available in different shapes and sizes, flexible treatment of various wounds is possible. Cutimed Sorbact uses a natural approach to wound healing, with no chemically active agents, using only the physical principle of hydrophobic interaction. There are no known sideeffects, allergy risk, cytotoxicity, or risk of bacterial and fungal resistance. The simplicity and adaptability of this bacterial binding product should be considered a welcome product development. WUK References Key Points 8 A 116-patient multicentre assessment looked at the efficacy of Cutimed Sorbact as an antimicrobial dressing. 8 Cutimed Sorbact binds and removes bacteria without charging the wound with a chemically active agent. 8 The evaluation considered the dressing s ability to reduce inflammation, eliminate local infection and improve the course of wound healing. It also examined how well the dressing was tolerated by patients and its ease of use for clinicians. 8 The study found that 81% of the patients with an infected wound received effective treatment. Twenty-one per cent of all the wounds healed during the study and 7 showed improvements. There was a marked improvement in pain symptoms and the majority of patients were very positive in their evaluation of the product. It was also well received by clinicians with 97% rating it as good or very good. Cutting KF, Harding KG (1994) Criteria for identifying wound infection. J Care 3(4): 198 201 Gray D, Cooper P, Timmons J (2006) Essential Management. An Introduction for Undergraduates. s UK, Aberdeen Schulz G, Sibbald RG, Falanga V et al (2003) bed preparation: a systematic approach to wound management. Rep Regen 11: 1 28 Sibbald RG, Williamson D, Orsted H, et al (2000) Preparing the wound Debridement, bacterial balance, and moisture balance. Ostomy Manag 46: 14 35 Ljungh A, Yanagisawa N, Wadström T (2006) Using the principle of hydrophobic interaction to bind and remove wound bacteria. J Care 15(4): 175 80